B. Stein

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

Jan B. Vermorken, Jan Stöhlmacher-Williams, Lisa Licitra et al. · The Lancet Oncology · 2013 · 433 citations · Full text

Medicine, Oncology, Chemotherapy +10

Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial

B. Stein, Nicholas J. Petrelli, Harold O. Douglass et al. · Cancer · 1995 · 273 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

Danny Rischin, Michael R. Migden, Annette M. Lim et al. · Journal for ImmunoTherapy of Cancer · 2020 · 175 citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma

Danny Rischin, Sandro Porceddu, Fiona Day et al. · New England Journal of Medicine · 2025 · 60 citations

Medicine, Oncology, Pharmacotherapy +17

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6

Brett Hughes, Alexander Guminski, Samantha Bowyer et al. · Journal of the American Academy of Dermatology · 2024 · 59 citations

Medicine, Dermatology, Oncology +15